Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8701 Monotherapy and with Durvalumab in Advanced Solid Tumors
NCT04504669Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Primary completion
- Oct 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 4
01
Overview
Phase 1, open-label trial of AZD8701 in solid neoplasms, head and neck squamous cell carcinoma (HNSCC), triple negative breast cancer (TNBC) and 6 more (2 arms), sponsored by AstraZeneca. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose assessed through AEs and SAEs, Maximum Tolerated Dose and Recommended Phase 2 Dose assessed through DLTs and 3 more. Started Aug 2020; status: completed.
02
Drugs
AZD8701
03
Conditions
solid neoplasmshead and neck squamous cell carcinoma (HNSCC)triple negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04504669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504669.